Tactile Systems Technology, Inc. announced on February 4, 2025, that its next-generation pneumatic compression platform, Nimbl, is now commercially available throughout the United States for the treatment of both upper and lower extremity lymphedema.
This expansion follows the initial commercial launch for upper extremity lymphedema in October 2024. Nimbl had previously received U.S. Food & Drug Administration (FDA) 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding (PDAC) approval from the Centers for Medicare & Medicaid Services (CMS) in September 2024.
The Nimbl platform is designed to be 68% lighter, 40% smaller, and uses 33% less hosing than the company’s previous basic pneumatic compression device. Its compact design and connectivity to the Kylee™ digital application aim to increase patient adherence and improve clinical outcomes for a broader patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.